For decades, hepatitis E virus (HEV) genotypes 1 and 2, transmitted via the fecal-oral route, have been known to be responsible for waterborne outbreaks of infection in developing countries. In recent years, HEV genotypes 3 and 4 have been found to be endemic in developed countries, causing sporadic autochthonous zoonotic infections, mostly by the consumption of raw or undercooked pork, wild boar or deer. 1 In immunocompetent individuals, HEV infection is most of the time asymptomatic or presents as acute non-severe self-limiting hepatitis, except in pregnant women and in patients with underlying chronic liver disease who can develop acute fulminant hepatitis. 2 Conversely, in immunocompromised patients such as solid organ transplant (SOT) recipients, 3 patients suffering from hematological malignancies treated by chemotherapy and/or stem cell transplantation 4 and more rarely from HIV, HEV infections have been reported to cause chronic hepatitis rapidly leading to cirrhosis. We note that reports of acute hepatitis in such patients are rare, including in patients who have undergone allogeneic stem cell transplantation (allo-HSCT).
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A 60-year-old woman was transferred to our hematology unit for acute liver failure 80 days after an allo-HSCT. Apart from breast cancer 8 years previously, she had no significant comorbidities, notably no hepatic disease or excessive alcohol consumption and had not traveled abroad recently. At the end of 2014 she was diagnosed with Ph ALL and treated with systemic polychemotherapy together with Imatinib and intrathecal chemotherapy for central nervous system prophylaxis. CR and major molecular response were obtained and she underwent an allograft from a HLA 9/10-mismatched unrelated donor following a myeloablative conditioning regimen that included TBI (8 Gray), Fludarabine (120 mg/m 2 ) and rabbit antithymocyte globulin (5 mg/m 2 ). GvHD prophylaxis associated Methotrexate and Cyclosporin A. Her ANC was 4500/μL at day 18. At day 25, she presented an acute confused state and cerebellar ataxia explored by cerebral magnetic resonance imaging and cerebrospinal fluid analysis. No pathological finding was detected but Cyclosporin A toxicity was suspected and consequently the latter was replaced by Mycophenolate mofetil. One month post transplant, the patient achieved a deep molecular response and full blood donor chimerism. The CD4+ lymphocyte count was null and liver enzymes were strictly normal. At day 50, the patient developed grade II acute cutaneous GvHD that was resolved with systemic corticosteroids at a dose of 1 mg/kg/d. At day 70, she was admitted to her local hospital for febrile diarrhea, vomiting and dehydration. Blood analysis revealed a moderate increase in hepatic markers ( Figure 1 ). Clostridium difficile colitis was confirmed on stool analysis and treated by oral Metronidazole followed, because of failure, by oral Vancomycin. Of note, no acetaminophen was used in this context of hepatitis. Given the persistent worsening in liver function the patient was transferred to our tertiary-level hospital at day 81. The clinical examination revealed fever, excessive weakness, jaundice and nonhemorrhagic diarrhea. Laboratory parameters continued to deteriorate and pancytopenia appeared. An abdominal Doppler ultrasound revealed no sinusoidal obstruction syndrome (SOS) or portal hypertension. Hepatitis viruses were determined by serological (Hepatitis A virus (HAV), Hepatitis B virus (HBV), Hepatitis C virus (HCV) and HEV) and molecular (CMV, EBV, HAV, HBV, HCV, HEV, Adenovirus, VZV and HSV) analysis. A trans-jugular liver biopsy was performed. Finally, to address the pancytopenia, a bone marrow aspirate confirmed the CR. Our empirical therapeutic strategy was immediately started and guided by the two most frequent diagnoses in the context: acute hepatic GvHD and druginduced liver injury (DILI). All potential hepatotoxic drugs were stopped and a course of IV corticosteroids (2 mg/kg/day) was initiated, complementary to supportive care including IV Nacetylcysteine supplementation. Despite these measures, liver dysfunction rapidly evolved to severe hepatic failure. At day 84, the patient developed severe intestinal bleeding leading to hemorrhagic shock and multi-organ failure justifying her transfer to the intensive care unit. In spite of maximum intensive organ supportive care, the hemorrhagic syndrome was out of control and she died the same day. The initial gravity and rapid degradation in health status excluded the option of an urgent liver transplant. Liver histopathology revealed hepatocyte necrosis and various hepatocyte nuclear abnormalities, features suggesting a viral etiology. Furthermore, venular blockage and hemorrhagic necrosis in favor of SOS were absent, and no argument for a shock liver was retained. Finally, the blood virus screening, obtained post mortem, was negative except for HEV-specific RT-PCR revealing a high load of HEV RNA confirming the diagnosis of acute fulminant hepatitis E. Sequencing of the viral ORF2 region combined with phylogenetic analysis demonstrated genotype 3 f (National Reference Center, Toulouse, France). Anti-HEV IgM Ab was negative. To determine the route of transmission, retrospective screening of the patient's freeze-stored sera for quantitative HEV RNA was performed. Viremia appeared after initiation of the chemotherapy courses and before the transplantation, excluding de facto transmission from the donor, which was confirmed by negative HEV RNA in serum and cells. Furthermore, transfusionrelated transmission was ruled out by testing the entire transfused blood products. Thus, the source of the infection was probably due to food contamination but the patient's dietary history could not be obtained.
A first series of hepatitis E in immunocompromised patients was reported in kidney and liver transplant recipients 3 followed by numerous reports in various types of SOT. No acute severe form has been reported but chronic evolution was the major complication. Concerning allo-HSCT, the largest cohort was 328 patients with a reported incidence rate of acute HEV of 2.4% and a risk of developing chronic hepatitis of 63%. 4 Nevertheless, two other studies based on much smaller series of patients reported a low risk of chronic HEV infection. 6, 7 Notably, none of the recipients experienced acute severe hepatitis. Pfefferl et al. 5 reported the only case of HEV-induced fatal acute liver failure in a patient with chronic kidney disease requiring hemodialysis, long after an allo-HSCT but only several weeks after donor lymphocyte and Rituximab infusions.
In chronic form, the impaired immune response is responsible for incomplete clearance of the virus, exacerbated by a significantly low level of CD4+ lymphocytes in chronically infected patients. 3, 8 The completion of viral clearance occurs only after reduction or withdrawal of the immunosuppressive drugs. 8 However, the pathophysiology is less straightforward in patients presenting with an acute fulminant infection. Low CD4+ lymphocyte counts and greater viral load in fulminant immunocompetent cases argue for direct viral cytotoxicity. 9 On the contrary, high titers of IgG Ab have been correlated with more severe acute HEV, raising the potential toxicity of the host's immune response, clearly described for other viruses. 9 In our patient, viremia increased shortly after transplant and then deeply declined together with a rise of the lymphocyte count. Finally, 3 weeks after initiation of corticosteroids, viremia significantly raised, arguing, together with the absence of seroconversion and the deep lymphopenia, for direct viral toxicity.
Hepatitis E is underdiagnosed and should always be considered when liver enzymes are increased in pre-and post-allo-HSCT follow-up so as not to be misdiagnosed as DILI or GvHD. 10 Serological methods have some limitations in immunocompromised patients given their frequently impaired Ab production. PCR of serum and stools provides much better sensitivity and should be preferred. 11 The most frequent route of HEV transmission in developed countries is the consumption of undercooked meat. Thus prevention depends on patient education concerning dietary rules pre and post allo-HSCT. In addition, transfusion-transmitted HEV infections have been described in immunocompromised patients. 12 Even though the prevalence of viremia in blood donors is low, the high transmission rate and the potential for severe HEV-related adverse events and death should urge transfusion physicians to revise recommendations on blood donor RNA screening. 13, 14 The same reflection is ongoing concerning donors of hematopoietic stem cells (HSC), although, as yet, no case of HSC-transmitted HEV has been reported. 15 Furthermore, there are currently no guidelines concerning HEV testing in recipients prior to transplantation. Effective prevention measures are all more important, as no effective treatment exists for acute fulminant cases.
In conclusion, we report the first case, to our knowledge, of fatal fulminant hepatitis E early after allo-SCT. Although HEV was not transmitted via blood transfusion in this case, future recommendations regarding HEV RNA screening in blood donors should reduce the risk of transfusion-transmitted HEV infections. In the field of allo-HSCT, systematic screening of HSC donors and recipients should also be discussed.
